Objective: To elucidate the pharmacological material basis of Danggui Buxue Decoction for its "blood-tonifying" effect through spectrum-effect relationship analysis.
Methods: The chemical constituents of Danggui Buxue Decoction were qualitatively analyzed using liquid chromatography-quadrupole-orbitrap mass spectrometry (LC-QE/MS). An ultra-performance liquid chromatography (UPLC) fingerprint of Danggui Buxue Decoction was established, and the common peaks of 30 batches of self-made Danggui Buxue Decoction were quantitatively analyzed. A zebrafish anemia model induced by phenylhydrazine was established, and the spectrum-effect relationship analysis method was applied to correlate the pharmacological data of 30 batches of Danggui Buxue Decoction with the fingerprint data to screen for its pharmacological material basis.
Results: A total of 90 prototype components were identified in the qualitative analysis of Danggui Buxue Decoction. The UPLC fingerprint of Danggui Buxue Decoction and the zebrafish anemia model were successfully established. The spectrum-effect relationship analysis of the pharmacological data and fingerprint data of 30 batches of Danggui Buxue Decoction revealed that the pharmacological materials of Danggui Buxue Decoction included 4-guanidinobutanoic acid (from Astragalus), isoleucine (from wine-prepared Angelica), lauric acid (from wine-prepare Angelica), ferulic acid (from both wine-prepared Angelica and Astragalus), 6-methoxy-2H-chromen-2-one (from both wine-prepared Angelica and Astragalus), sophoraisoflavone glucoside (from both wine-prepared Angelica and Astragalus), and an unknown peak 8.
Conclusion: This study screened the pharmacological material basis of Danggui Buxue Decoction through qualitative and quantitative analysis of its prototype chemical constituents combined with spectrum-effect relationship analysis, providing scientific support for the clinical application and secondary development of this classic prescription.